Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

Por um escritor misterioso
Last updated 19 setembro 2024
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research describing ASDAS LDA achievement among patients treated with biologic DMARDs (bDMARD) is limited. The aim of this study was to describe disease activity and patient-reported outcome measures (PROMs) among patients […]
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Safety Profile, Axial Spondyloarthritis
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Performance of 3 Composite Measures for Disease Activity in
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Impact of Achieving Minimal Disease Activity on Patient-Reported
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Canadian Rheumatology Association Meeting Quebec City Convention
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Full article: Effectiveness of bDMARDs in ankylosing spondylitis
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Safety Profile, Axial Spondyloarthritis
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Impact of Achieving ASDAS LDA on Disease Activity and Patient
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
PDF) Efficacy and safety of upadacitinib in patients with
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
ARA Abstracts - 2020 - Internal Medicine Journal - Wiley Online
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Upadacitinib efficacious in patients with ankylosing spondylitis
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
PDF) Impact of Secukinumab on Patient-Reported Outcomes in the
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Disease Activity-Guided Stepwise Tapering but Not Discontinuation
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Effect of body mass index on treatment response of biologic

© 2014-2024 galemiami.com. All rights reserved.